Barclays’s Pacira BioSciences PCRX Stock Holding History

Barclays’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-100	Closed	-$4K	–	6695
2019 Q3	$4K	Sell	100 -900	-90%	-$35.9K	﹤0.01%	6483
2019 Q2	$43K	Buy	+1,000	New	+$42.5K	﹤0.01%	6169
2018 Q4	–	Sell	-500	Closed	-$25K	–	7230
2018 Q3	$25K	Hold	500	–	–	﹤0.01%	6399
2018 Q2	$16K	Sell	500 -164,500	-100%	-$5.68M	﹤0.01%	6304
2018 Q1	$5.14M	Buy	165,000 +139,800	+555%	+$4.98M	﹤0.01%	1619
2017 Q4	$1.15M	Sell	25,200 -82,700	-77%	-$3.28M	﹤0.01%	2979
2017 Q3	$4.05M	Buy	107,900 +106,700	+8,892%	+$4.29M	﹤0.01%	1701
2017 Q2	$57K	Sell	1,200 -4,300	-78%	-$200K	﹤0.01%	5275
2017 Q1	$251K	Buy	+5,500	New	+$238K	﹤0.01%	4088
2015 Q3	–	Sell	-53,900	Closed	-$3.77M	–	6985
2015 Q2	$3.77M	Buy	+53,900	New	+$4.24M	﹤0.01%	1722
2014 Q3	–	Sell	-2,000	Closed	-$182K	–	7776
2014 Q2	$182K	Hold	2,000	–	–	﹤0.01%	4907
2014 Q1	$138K	Buy	+2,000	New	+$136K	﹤0.01%	5148
2013 Q3	–	Sell	-10,800	Closed	-$313K	–	7553
2013 Q2	$313K	Buy	+10,800	New	+$312K	﹤0.01%	4735

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's PCRX Position: Q1 2026 in Review

Barclays reduced its Pacira BioSciences (PCRX) stake by 19% in Q1 2026, selling an estimated $1.5M and leaving 282,108 shares worth $6.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Barclays first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.3M in Q1 2017. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Barclays held 282,108 shares of Pacira BioSciences worth $6.38M as of Q1 2026.
Barclays sold 67,334 Pacira BioSciences shares in Q1 2026, an estimated $1.5M.
Pacira BioSciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1678 holding.
Barclays first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
Barclays's Pacira BioSciences position peaked at $12.3M in Q1 2017.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.